Predix Pharmaceuticals' Drug Candidates to Be Featured at Upcoming Biomedical Conferences; Presentations to Highlight Recent Studies With PRX-03140, PRX-08066 and PRX-07034.LEXINGTON, Mass. -- Predix Pharmaceuticals, which recently announced a definitive agreement to merge with EPIX EPIX Emergency Preparedness Information Exchange EPIX Enhanced Performance unIX EPIX European Property Stock Index Pharmaceuticals (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : EPIX), announced today that data featuring select drug candidates currently in clinical development will be the subject of presentations at major medical and scientific meetings in the next few weeks. "The data selected for presentation at these meetings illustrates the quality of the drug candidates discovered at Predix," said Michael G. Kauffman, M.D., Ph.D., president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Predix Pharmaceuticals. "We continue advancing our candidates in clinical trials and recently announced the initiation of a clinical trial of our fourth novel drug candidate, PRX-07034, the fourth internally-discovered compound to enter clinical trials in fewer than four years." Preclinical data will be presented on: PRX-03140, a highly selective, proprietary serotonin 4 (5-HT4) receptor agonist agonist /ag·o·nist/ (ag´ah-nist) 1. one involved in a struggle or competition. 2. agonistic muscle. 3. being developed for Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. ; PRX-08066, a highly selective, proprietary 5-HT2B receptor antagonist A receptor antagonist is a drug that does not provoke a biological response itself upon binding to a receptor, but blocks or attenuates agonist-mediated responses. It may be competitive (or surmountable), i.e. being developed for the treatment of pulmonary hypertension Pulmonary Hypertension Definition Pulmonary hypertension is a rare lung disorder characterized by increased pressure in the pulmonary artery. The pulmonary artery carries oxygen-poor blood from the lower chamber on the right side of the heart (right (PH) and PH associated with chronic obstructive pulmonary disease chronic obstructive pulmonary disease n. Abbr. COPD A chronic lung disease, such as asthma or emphysema, in which breathing becomes slowed or forced. ; and PRX-07034, a highly selective, proprietary 5-HT6 receptor antagonist being developed for the treatment of obesity and also for cognitive impairment (associated with Alzheimer's disease or schizophrenia). The schedule and conferences are listed below: PRX-03140: Selective 5-HT4 Agonist July 18, 2006 at the 10th International Conference on Alzheimer's Disease in Madrid, Spain Oral Presentation Title: PRX-03140: A Novel 5-HT4 Partial Agonist with a Dual Cholinergic/Disease-Modifying Mechanism for the Treatment of Alzheimer's Disease Presenter: Sharon Shacham, Ph.D., Predix Pharmaceuticals PRX-08066: Selective 5-HT2B Antagonist June 23, 2006 at the Pulmonary Hypertension Association's 7th International Conference and Scientific Sessions in Minneapolis, MN Presentation Title: PRX-08066: A Potent 5-HT2B Receptor Antagonist with a Dual Disease Modifying/Vasodilating Mechanism for the Treatment of Pulmonary Hypertension Presenter: Sharon Shacham, Ph.D., Predix Pharmaceuticals PRX-07034: Selective 5-HT6 Antagonist June 27-30, 2006 at the Serotonin Club Meeting in Sapporo, Japan (two presentations) Presentation Title: Combination of Sub-Threshold Doses of Aricept and PRX-07034, a Novel 5-HT6 Receptor Antagonist, Enhances Novel Object Discrimination (NOD) Memory Presenter: M.V. King, University of Nottingham Medical School The University of Nottingham Medical School is a medical school in the city of Nottingham, UK. It was the first new medical school to be set up in the 20th century in the country, with the first intake of 48 students graduating in 1975. Presentation Title: PRX-07034, a Potent and Selective 5-HT6 Receptor Antagonist, Reduces Food Intake and Body Weight in Rats Presenter: Kimberley Gannon, Ph.D., Predix Pharmaceuticals July 23-26, 2006 at the British Association for Psychopharmacology psychopharmacology (sī'kōfär'məkŏl`əjē), in its broadest sense, the study of all pharmacological agents that affect mental and emotional functions. in Oxford, UK Presentation Title: Sub-Threshold Doses of Aricept and a Novel 5-HT6 Receptor Antagonist, PRX-07034, Interact To Enhance Memory in the Novel Object Discrimination (NOD) Task Presenter: M.V. King, University of Nottingham Medical School About Predix Pharmaceuticals Holdings, Inc. Predix, based in Lexington, MA, is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels. Using its proprietary drug discovery technology and approach, Predix has advanced four internally-discovered drug candidates into clinical trials and has five additional programs in preclinical development and discovery. Predix is expected to complete the first of at least two pivotal Phase III clinical trials Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the for generalized anxiety disorder Generalized Anxiety Disorder Definition Generalized anxiety disorder is a condition characterized by "free floating" anxiety or apprehension not linked to a specific cause or situation. for its lead drug candidate, PRX-00023, in the second half of 2006. In addition to PRX-00023, Predix has three other clinical-stage drug candidates: PRX-03140 for the treatment of Alzheimer's disease, which is expected to enter Phase IIa later this year; PRX-08066 for the treatment of pulmonary hypertension (PH) and PH associated with chronic obstructive pulmonary disease, which recently completed a Phase Ib trial and is expected to enter Phase IIa in mid-2006; and, PRX-07034, which recently entered a Phase I trial and is expected to be developed for the treatment of obesity and also cognitive impairment associated with Alzheimer's disease or schizophrenia. Additional information about Predix can be found on the company's website at www.predixpharm.com. Additional Information About the Merger And Where To Find It EPIX has filed a registration statement on Form S-4 with the Securities and Exchange Commission containing a joint proxy statement/prospectus in connection with the proposed merger with Predix. Investors and security holders are advised to read the joint proxy statement/prospectus (including any amendments or supplements thereto) regarding the proposed merger because it contains important information about EPIX, Predix and the proposed transaction and other related matters. The joint proxy statement/prospectus will be sent to stockholders of EPIX and Predix seeking their approval of the proposed transaction. Investors and security holders may obtain a free copy of the joint proxy statement/prospectus and any amendments or supplements thereto and other documents filed by EPIX at the Securities and Exchange Commission's web site at www.sec.gov. The joint proxy statement/prospectus and such other documents may also be obtained for free by directing such request to EPIX Pharmaceuticals, Inc. 161 First Street, Cambridge, Massachusetts This article is about the city of Cambridge in Massachusetts. For the English university town, see Cambridge, England. For other places, see Cambridge (disambiguation). Cambridge, Massachusetts is a city in the Greater Boston area of Massachusetts, United States. , Attn: Investor Relations Investor relations The process by which the corporation communicates with its investors. , tel: (617) 250-6000; e-mail: ahedison@epixpharma.com or Predix Pharmaceuticals Holdings, Inc., 4 Maguire Road, Lexington, Massachusetts Lexington is a town in Middlesex County, Massachusetts, United States. The population was 30,355 at the 2000 census. The town is famous for being the site of the opening shots of the Battles of Lexington and Concord, the first engagement of the American Revolution. 02421, Attn: Investor Relations, tel: (781) 372-3260; e-mail: investors@predixpharm.com. EPIX and Predix and their respective directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies with respect to the adoption of the merger agreement and the transactions associated with the merger. A description of any interests that EPIX and Predix directors and executive officers have in the merger is included in the registration statement containing the proxy statement/prospectus that has been filed with the Securities and Exchange Commission and is available free of charge as indicated above. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement Certain statements in this news release concerning Predix's business are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These statements include, but are not limited to, those relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc the timing and results of future clinical development of PRX-00023, the potential efficacy of PRX-00023 and the expected safety and tolerability of PRX-00023 as compared to other drugs treating anxiety. Any or all of the forward-looking statements in this press release can be affected by inaccurate assumptions Predix might make or by known or unknown risks and uncertainties, including, but not limited to: the early stage of product development; uncertainties as to the future success of ongoing and planned clinical trials; and the unproven safety and efficacy of products under development. Consequently, no forward-looking statement can be guaranteed, and actual results may vary materially. Predix undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion